Financial Performance - The company reported total revenue of RMB 1,596.3 million for the fiscal year ending December 31, 2023, representing a 7.5% increase compared to RMB 1,484.9 million in 2022[20]. - Net profit attributable to shareholders reached RMB 85.9 million, a turnaround from a loss of RMB 24.2 million in 2022, with a return on equity of 7.0%[20]. - For the fiscal year 2023, the group achieved revenue of RMB 1,596.3 million, a 7.5% increase from 2022, with self-operated hospital revenue rising by 8.7% to RMB 1,485.2 million[25]. - The gross profit margin for self-operated hospitals improved to 25.4% in 2023, up from 23.9% in 2022, leading to an overall gross profit increase of 16.5% to RMB 411.1 million[25]. - The company's net profit for the year 2023 reached RMB 86,931,608, a significant recovery from a net loss of RMB 10,968,839 in 2022, marking a turnaround of over 800%[132]. - Operating profit increased to RMB 101,451,680 in 2023, compared to RMB 16,391,934 in 2022, reflecting a growth of approximately 518%[130]. - Basic earnings per share for the year 2023 were both RMB 1.15, recovering from a loss of RMB 0.32 per share in 2022[134]. Revenue Sources - The operating revenue from self-owned hospitals was RMB 1,485.2 million, an increase of 8.7% from RMB 1,366.8 million in the previous year[20]. - The group’s self-operated hospital billing revenue reached RMB 1,537.4 million, a 7.9% increase driven by higher outpatient and inpatient visits[30]. - The total inpatient revenue was RMB 1,319.1 million, an increase from RMB 1,218.3 million in 2022[33]. - Outpatient billing revenue was RMB 218.3 million, up 5.6% year-over-year, attributed to a 5.0% decrease in outpatient visits and an 11.2% increase in average spending per visit[35]. - Other medical-related business revenue was RMB 105.8 million, with non-hospital drug and medical device sales contributing RMB 64.4 million[39]. Cost and Expenses - The total cost of revenue for self-owned hospitals increased to RMB 1,107.9 million, a growth of 6.5% compared to 2022, primarily due to a 7.7% increase in costs related to drug sales and an 11.6% rise in employee benefits and expenses[38]. - Research and development expenses amounted to RMB 32.5 million, a decrease of 1.7% from 2022, representing 2.2% of the group's self-owned hospital operating revenue[49]. - The group's management expenses were RMB 213.0 million, an increase of 3.5% year-over-year, with management expenses accounting for 14.3% of self-owned hospital operating revenue[53]. - Financial expenses netted RMB 41.5 million, a decrease of RMB 2.9 million from 2022, with borrowing interest expenses down by 9.1% due to lower bank loan rates[56]. Assets and Liabilities - Total assets increased to RMB 3,047.7 million as of December 31, 2023, from RMB 2,637.8 million in 2022[11]. - The company's total liabilities increased to RMB 801,130,416 in 2023, compared to RMB 657,446,340 in 2022, which is an increase of approximately 21.8%[140]. - The company's debt-to-asset ratio increased to 53.8% as of December 31, 2023, compared to 49.7% as of December 31, 2022, mainly due to the increase in bank loans[92]. - Accounts receivable increased by 9.8% to RMB 420.4 million as of December 31, 2023, up from RMB 382.8 million in 2022, attributed to higher operating income from self-owned hospitals[64]. Cash Flow - Cash generated from operating activities was RMB 265.0 million, compared to RMB 227.2 million in 2022[11]. - Net cash used in investing activities was RMB 215.0 million, primarily due to investments in property, plant, and equipment totaling RMB 179.7 million[76]. - Cash flow from operating activities generated CNY 265,033,237 in 2023, compared to CNY 227,220,564 in 2022, marking an increase of approximately 16.6%[143]. - Cash flow from investing activities showed a net outflow of CNY 215,017,085 in 2023, an improvement from a net outflow of CNY 273,615,413 in 2022[145]. Strategic Initiatives - The company is focusing on enhancing mental health services and expanding its elderly care segment in response to increasing demand and supportive government policies[13]. - The company has implemented a regional management model that has shown positive effects, particularly in the Taizhou and Haixi regions, with stable growth in self-owned hospitals[21]. - The group acquired 51% stakes in Loudi Kangning Hospital and Dongkou Lening Hospital, as well as controlling interest in Chengdu Yining Hospital, enhancing its strategic network in the mental health sector[22]. - The company plans to address the losses from Beijing and Shenzhen hospitals due to high property costs through comprehensive strategies[21]. Shareholder Information - The company proposed a final cash dividend of RMB 3 per 10 shares, totaling RMB 22,380,090, which represents 26.0% of the net profit attributable to shareholders for the reporting period[100]. - The total cash dividend for the 2023 interim and proposed final dividends combined is RMB 29,840,120, accounting for 34.7% of the net profit attributable to shareholders[100]. - No shareholders waived or agreed to waive any dividends as of December 31, 2023[105]. Compliance and Governance - The audit committee, consisting of independent non-executive directors, reviewed the financial performance and confirmed compliance with applicable accounting standards[108]. - The company has complied with all corporate governance code provisions during the reporting period[109]. - There were no significant post-reporting period events that could impact the financial statements[113].
康宁医院(02120) - 2023 - 年度业绩